What is Accumetrics?
Accumetrics is a pioneering force in the field of diagnostic medical technology, specifically dedicated to the assessment of platelet function. The company is best known for its VerifyNow System, a proprietary, rapid-response platform that enables clinicians to evaluate an individual patient's response to various antiplatelet agents. By providing real-time, actionable data, the VerifyNow System assists physicians in making informed, personalized treatment decisions for patients undergoing therapy with aspirin, P2Y12 inhibitors, and GP IIb/IIIa inhibitors. This technology addresses a critical gap in clinical practice, where traditional testing methods often lack the speed and accessibility required for acute care environments. Through its commitment to advancing medical understanding, Accumetrics plays a vital role in improving patient outcomes and optimizing therapeutic efficacy across the cardiovascular and surgical care spectrums.
How much funding has Accumetrics raised?
Accumetrics has raised a total of $6M across 1 funding round:
Private Equity
$6M
Private Equity (2013): $6M with participation from SightLine Partners, LLC, Essex Woodlands Health Ventures, and RiverVest Venture Partners, LLC
Key Investors in Accumetrics
SightLine Partners, LLC
SightLine Partners is a specialized investment firm that focuses on providing growth capital to healthcare and life science companies, often targeting businesses with established technologies.
Essex Woodlands Health Ventures
EW Healthcare Partners is a healthcare growth equity firm that invests in companies across the US and Europe, focusing on driving positive change in healthcare while achieving high returns.
RiverVest Venture Partners, LLC
RiverVest is a prominent venture capital firm focused on building life science companies to meet significant unmet medical needs through science, strategy, and innovation.
What's next for Accumetrics?
With the successful closure of this major strategic investment, Accumetrics is well-positioned to accelerate its commercialization efforts and expand the clinical utility of the VerifyNow System. The company is expected to focus on deepening its market penetration within hospital systems and specialized cardiac centers, where rapid platelet function assessment is essential for managing high-risk patients. Furthermore, the capital will likely support ongoing research and development initiatives aimed at broadening the diagnostic scope of the VerifyNow platform to include emerging antiplatelet therapies. By maintaining its focus on high-impact clinical diagnostics, Accumetrics is poised to remain at the forefront of the precision medicine movement, driving long-term value for both its clinical partners and its strategic investors.
See full Accumetrics company page
